Press Release
June 25, 2025
Avigena Biosciences is proud to announce that its co-founders have been granted Patent No.
13249 and 13250 by Lebanon’s Intellectual Property Protection Office (IPPS) for the
development of proprietary Polygenic Risk Scores (PRS) for Coronary Artery Disease (CAD)
and Breast Cancer (BC)—the first PRS models tailored for Arab and Middle Eastern
populations.
This milestone marks a major scientific breakthrough, providing regionally optimized genomic
tools that improve disease risk prediction and support Avigena’s mission to deliver equitable,
preventive precision care across the Arab world and beyond.